Clinical trials: Glomerulosclerosis, Focal Segmental
Focal Segmental Glomerulosclerosis
Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS
This study will investigate whether GC1008, an antibody which neutralizes TGF-beta, is safe in treating patients with the disease called focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT00464321
- Testing
- GC1008
- Where
- 9 sites in United States, Germany and 2 more
- Volunteers
- 16 people
- Sponsor
- Genzyme, a Sanofi Company
Glomerulonephritis, Membranous, Glomerulosclerosis, Focal
Mycophenolate Mofetil in Membranous Nephropathy and Focal Segmental
This is a prospective randomized open-label pilot study to investigate the effect of mycophenolate mofetil treatment in patients with abnormal urine protein excretion due to membranous nephropathy (MN) or focal segmental…
- Trial name
- NCT00404833
- Testing
- prednisolone and mycophenolate mofetil, prednisolone and chlorambucil
- Where
- China
- Volunteers
- 16 people
- Sponsor
- Hospital Authority, Hong Kong
Focal Segmental Glomerulosclerosis, Nephrotic Syndrome
Cardiomyopathy in Steroid-resistant Nephrotic Syndrome: Impact of Focal Segmental Glomerulosclerosis
The objective of this study is as follows: Perform genetic analysis to define the prevalence of each of the known gene mutations in an unselected cohort of patients with focal segmental glomerulosclerosis (FSGS) Perform a…
- Conditions
- Focal Segmental Glomerulosclerosis, Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Chronic Kidney Disease
- Trial name
- NCT00883636
- Testing
- Cardiovascular Assessment, Renal Assessment, Genetic Evaluation
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Northwell Health
Focal Glomerulosclerosis
Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis
The purpose of this study is to assess the efficacy of Tacrolimus Treatment of patients with idiopathic focal segmental glomerulosclerosis.
- Trial name
- NCT00302536
- Testing
- Tacrolimus
- Where
- China
- Volunteers
- healthy volunteers welcome
- Sponsor
- Nanjing University School of Medicine
Nephrosis, Focal Lipoid Glomerulosclerosis
Steroid Treatment for Kidney Disease
Focal segmental glomerulosclerosis (FSGS) and minimal change disease are kidney diseases that are associated with increased excretion of protein in the urine.
- Trial name
- NCT00065611
- Testing
- Oral dexamethasone
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Proteinuria, Focal Segmental Glomerulosclerosis
Prednisone Plus Tripterygium Wilfordii Treatment of Adult Patients With Idiopathic Focal Segmental Glomerulosclerosis
The purpose of this study is to assess the efficacy of prednisone and tripterygium wilfordii in treated Focal Segmental Glomerulosclerosis (FSGS).
- Trial name
- NCT00801463
- Testing
- tripterygium wilfordii (TW)
- Where
- China
- Volunteers
- 67 people
- Sponsor
- Nanjing University School of Medicine
Focal Segmental Glomerulosclerosis
Therapeutic Effect of Low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis
The aim of this clinical trial is to determine the effect and security of low-dose Prednisone Combined With MMF and FK506 in Focal Segmental Glomerulosclerosis.
- Trial name
- NCT00956059
- Testing
- prednisone, FK506, MMF, prednisone
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Xi'an Jiaotong University
Glomerulonephritis, Nephrotic Syndrome
Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis
This study will test the safety and effectiveness of a monthly dosing regimen of dexamethasone-a strong steroid medication-to treat patients with focal segmental glomerulosclerosis (FSGS).
- Trial name
- NCT00004990
- Testing
- Dexamethasone
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Focal Glomerulosclerosis
Sirolimus for Focal Segmental Glomerulosclerosis
This study will determine the safety and effectiveness of sirolimus (Rapamune® (Registered Trademark)) in treating focal segmental glomerulosclerosis (FSGS), a disease involving kidney scarring and increased protein in the urine.
- Trial name
- NCT00040508
- Testing
- Sirolimus
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Focal Glomerulosclerosis
Pilot Studies of Novel Therapies to Treat Resistant Focal Segmental Glomerulosclerosis (FSGS)
The current management of primary FSGS is predicated on the assumption that the disease is caused by an immune-mediated disturbance in glomerular barrier function.
- Trial name
- NCT00193648
- Testing
- Rosiglitazone (Avandia), Adalimumab (Humira)
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Northwell Health
Glomerulosclerosis, Focal
Total Lymphoid Irradiation (TLI) to Prevent Focal Segmental Glomerulosclerosis (FSGS)Recurrence in the Renal Graft
The purpose was study the immunosuppression using total lymphoid irradiation plus Csa, MMF and prednisone pretransplant to prevent focal segmental glomerulosclerosis recurrence in the renal graft
- Trial name
- NCT00353535
- Testing
- Total Lymphoid irradiation
- Where
- Brazil
- Volunteers
- 10 people
- Sponsor
- University of Sao Paulo